Individuals with spinal cord injury have heart attacks and strokes more frequently, and much earlier in life. People with spinal cord injuries develop plaque in vessels much faster, and the reasons why are unclear. Doctors generally attributed the increased risk with weight gain and developing diabetes, but many studies have shown that even without these common factors, plaque in vessels is developing more often and faster. Endothelial cells are a single layer of cells that line all vessels in the body and plays an important role in vessel health. Damage to endothelial cells is known to lead to heart attacks and strokes. Past studies on endothelial cells of people with spinal cord injury have been unclear. The investigators have new data that these cells are unhealthy after spinal cord injury a measurement. This includes measuring endothelial health by directly altering its function using a catheter in the arm and measuring small particles in blood called endothelial microvesicles. If the project is successful, the investigators will learn important information on the health of endothelial cells after spinal cord injury. The investigators will also be able to use these markers of endothelial cell function to create treatments to improve vessel health and prevent heart attacks and strokes later in life in people with spinal cord injury.

Start Date01 Jun 2024

Sponsor / Collaborator

Craig Hospital

[+1]

NCT06043310 / RecruitingNot Applicable

Sex-specific Effects of Continuous Estrogen on Human in Vivo Microvascular Function

The goal of this study is to learn how long-term use of estrogen affects blood vessels in healthy adults who were assigned male at birth.
Participants will:
give one blood draw of 5 mL
have a camera placed under the tongue to take pictures of blood vessels
have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion
Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

Start Date02 Jun 2023

Sponsor / Collaborator

The Medical College of Wisconsin, Inc.

ACTRN12623000467639 / Not yet recruitingPhase 1

Dose response of afterload reduction with sodium nitroprusside on left ventricular filling pressure under veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support in adults

Start Date01 Jun 2023

Sponsor / Collaborator

Sydney Local Health District

100 Clinical Results associated with Sodium Nitroprusside

100 Translational Medicine associated with Sodium Nitroprusside

100 Patents (Medical) associated with Sodium Nitroprusside

13,588

Literatures (Medical) associated with Sodium Nitroprusside

01 Apr 2024·Journal of ethnopharmacology

Danhong formula alleviates endothelial dysfunction and reduces blood pressure in hypertension by regulating MicroRNA 24 - Phosphatidylinositol 3-Kinase-Serine/Threonine Kinase- Endothelial Nitric Oxide Synthase axis

Article

Author: Yang, Xiaohu ; Ye, He ; He, Shuang ; Lei, Shanshan ; Yang, Wenchao

ETHNOPHARMACOLOGICAL RELEVANCE:

Essential hypertension (EH) is one of the important risk factors of cardio-cerebrovascular diseases, and it can significantly increase the incidence and mortality of acute myocardial infarction, cerebral infarction and hemorrhage. Danhong Formula (DHF) was consisting of Radix et Rhizoma Salviae Miltiorrhizae (Salvia miltiorrhiza Bge., Labiatae, Danshen in Chinese) and Flos Carthami (Carthamus tinctorius L., Compositae, Honghua in Chinese) (Plant names have been checked with http://www.the plant list.org on June 28th, 2023) was approved by State Food and Drug Administration of China, that has been used for thousands of years in the treatment of cardiovascular diseases in China with proven safety and efficacy. Though our previous studies have found that DHF improved endothelial dysfunction (ED) and decreased high blood pressure (BP), the underlying mechanisms of its antihypertensive effect still remain unclear.

AIM OF THE STUDY:

This study investigated whether DHF regulated MicroRNA 24- Phosphatidylinositol 3-Kinase-Serine/Threonine Kinase- Endothelial Nitric Oxide Synthase (miR-24 - PI3K/AKT/eNOS) axis to produce antihypertensive effect and improve endothelial dysfunction.

MATERIALS AND METHODS:

Firstly, the chemical components of DHF were analyzed by UHPLC-MS. After that, BP was continuously monitored within the 1st, 3rd, and 4th week in SHR to evaluate the antihypertensive effect of DHF intraperitoneal injection. In addition, not only the contents of serum nitric oxide (NO), prostacyclin (PGI₂), and angiotensin II (Ang II) were detected, but also the isolated aorta ring experiment was conducted to evaluate the vasomotoricity to evaluate of DHF on improving endothelial dysfunction. Key proteins or mRNA expression associated with miR-24 - PI3K/AKT/eNOS axis in aorta were detected by capillary Western blot, immunohistochemistry or RT-PCR to explore the underlying mechanisms. Index of NO, Ang II PGI₂ and key proteins or mRNA expression were also conducted in miR-24-3p over-expression HUVECs model.

RESULTS:

Compared with SHR control group, DHF (4 mL/kg/day, 2 mL/kg/day, 1 mL/kg/day) treatment significantly reduced high BP in SHR and selectively increased acetylcholine (Ach) induced vasodilation, but not sodium nitroprusside (SNP) in a manner of concentration dependency in isolated aorta ring. DHF (4 mL/kg/day, 1 mL/kg/day) treatment was accompanying an increment of NO and PGI₂, and lowering AngII in SHR. Moreover, DHF treatment significantly up-regulated expression of p-PI3K, p-AKT, mTOR, eNOS and p-eNOS, but down-regulated miR-24-3p expression in aorta. Compared with miR-24-3p over-expression HUVECs model group, DHF treatment inhibited miR- 24-3p expression and up-regulated p-PI3K, p-AKT, mTOR and eNOS mRNA expression. Similarly, DHF treatment increased PI3K, AKT, mTOR and eNOS protein expression in HUVECs by Western blot.

CONCLUSIONS:

These findings suggest that DHF alleviates endothelial dysfunction and reduces high BP in SHR mediated by down-regulating miR-24 via ultimately facilitating up-regulation of PI3K/AKT/eNOS axis. This current study firstly demonstrates a potential direction for antihypertensive mechanism of DHF from microRNA aspect and will promote its clinical applications.

01 Feb 2024·Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft

Interference of MDM2 attenuates vascular endothelial dysfunction in hypertension partly through blocking Notch1/NLRP3 inflammasome pathway

Article

Author: Liang, Jiao ; Fan, Zhengjun ; Wang, Huali ; Yang, Lihong ; Sun, Rongyan ; Zhou, Yubo

BACKGROUND:

Hypertension is a life-threatening disease mainly featured as vascular endothelial dysfunction. This study aims to explore the regulatory role of murine double minute 2 (MDM2) in hypertension and vascular damage.

METHODS:

Mice were infused with angiotensin II (AngII) to establish a hypertension mouse model in vivo and AngII-stimulated HUVECs were constructed to simulate the damage of vascular endothelial cells in hypertension in vitro. The plasmids targeting to MDM2 was injected to mice or transfected to HUVECs. qRT-PCR and western blot were performed to detect corresponding gene expression in mice aorta. Blood pressure was measured. H&E and Masson staining were conducted to evaluate histological changes of aorta. Responses to the acetylcholine (ACh) and sodium nitroprusside (SNP) were assessed in aorta. ZO-1 expression and cell apoptosis were detected by immunofluorescence and TUNEL, respectively. Network formation ability was determined employing a tube formation.

RESULTS:

MDM2 was upregulated in hypertensive mice. Knockdown of MDM2 inhibited AngII-induced high BP, histological damage, vascular relaxation to Ach, and promoted the levels of p-eNOS and ZO-1 in the aorta in hypertensive mice. MDM2 knockdown inactivated Notch1 signaling and NLRP3 inflammasome, while the inhibitory effect of MDM2 knockdown on NLRP3 inflammasome activation was partly restored by the activation of Notch1. Furthermore, knockdown of MDM2 relieved AngII-induced endothelial dysfunction in HUVECs, as well as suppressing AngII-promoted cell apoptosis. Whereas, the impacts generated by MDM2 knockdown were partly weakened by the activation of Notch1 signaling or NLRP3 inflammasome.

CONCLUSION:

In summary, knockdown of MDM2 can attenuate vascular endothelial dysfunction in hypertension, which may be achieved through inhibiting the activation of Notch1 and NLRP3 inflammasome.

01 Feb 2024·Carbohydrate polymers

Bifunctional drug delivery system with carbonic anhydrase IX targeting and glutathione-responsivity driven by host-guest amphiphiles for effective tumor therapy

Article

Author: Wang, Lutao ; Si, Tian ; Chen, Miao ; Zhou, Jiawei ; Li, Yamin ; Lv, Pin ; Tao, Jun ; Yang, Bo ; Xiao, Feijian

It remains a critical issue to deliver anticancer drugs to tumor tissues and reducing the toxic effects on normal tissues. The drug delivery system (DDS) based on self-assembly provides a multi-functional way for drug delivery. In this work, a supramolecular host (L-CD) with targeting function based on a β-cyclodextrin (β-CD) backbone was synthesized with carbonic anhydrase IX (CAIX) overexpressed on tumor cells as a target, and the methotrexate prodrug (MTX-SS-Ad) modified by adamantane and disulfide bond was prepared to be used as the guest. The amphiphilic complex was prepared between L-CD and MTX-SS-Ad through host-guest interactions and could further self-assemble into supramolecular nanoparticles (SNPs) with active targeting and stimulus release functions. The interaction between host and guest was investigated by UV, NMR, IR, XRD and TGA. The characteristic of SNPs was observed by DLS and TEM. Throng the study of molecular docking, in vitro inhibition, cell uptake experiments, and western blotting, SNPs have showed CAIX inhibitory effects both inside and outside the cells. The in vitro release experiments indicated that SNPs can undergo disintegration and release drugs under acidic and GSH conditions. Moreover, SNP can effectively inhibit the proliferation of cancer cells without generating additional toxic side effects on normal cells. So, we provide a strategy of bifunctional drug delivery system with targeting and glutathione-responsivity for effective tumor therapy.

News (Medical) associated with Sodium Nitroprusside

06 Apr 2023

·www.biospace.com

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2022

WINNIPEG, MB / ACCESSWIRE / April 6, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2022. Quarter and Year Ended December 31, 2022 Highlights: Recorded total net revenue of $23.1 million during the year ended December 31, 2022 compared to $21.7 million for the year ended December 31, 2021 and; Recorded total net revenue of $6.3 million during the quarter ended December 31, 2022 compared to $6.8 million for the quarter ended December 31, 2021 and; Recorded total net revenue from the sale of AGGRASTAT® of $11.7 million during the year ended December 31, 2022 compared to $11.5 million for the year ended December 31, 2021 and; Recorded total net revenue from the sale of ZYPITAMAG® of $3.6 million during the year ended December 31, 2022 compared to $3.2 million for the year ended December 31, 2021 and; Recorded total net revenue from the Marley Drug business of $7.8 million during the year ended December 31, 2022 compared to $6.9 million for the year ended December 31, 2021 and; Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the year ended December 31, 2022 was $3.3 million compared to adjusted EBITDA of $2.1 million for the year ended December 31, 2021 and; Net income for the year ended December 31, 2022 was $1.4 million or $0.13 per share compared to a net loss of $727,000 or $0.07 per share for the year ended December 31, 2021; Financial Results The increase in AGGRASTAT® revenues when compared to the same period in the previous year, as described above, is the result of increases in the volume of AGGRASTAT® sold in 2022 when compared to 2021, in conjunction to improvements in inventory and contract management. ZYPITAMAG® contributed $3.6 million of revenue for the year ended December 31, 2022 compared to $3.2 million for the year ended December 31, 2021. The increase in revenue is primarily as a result of uptake through covered plans and improved patient access and fill rate through Medicure's subsidiary Marley Drug, which also results in reduced fees to wholesalers and pharmacy benefit managers. The Marley Drug business, acquired on December 17, 2020, contributed $7.8 million of revenue for the year ended December 31, 2022 compared to $6.9 million for the year ended December 31, 2021. Marley Drug is a US pharmacy licensed to ship medications to all 50 states, Washington D.C. and Puerto Rico. It serves thousands of customers and provides another channel for direct-to-consumer marketing, distribution and improved profit margin for ZYPITAMAG. The increase in revenue is a result of marketing efforts to grow the customer base and sales through the newly launched E-commerce website. Sodium nitroprusside did not contribute any revenue during the year ended December 31, 2022 compared to $59,000 of revenue during the year ended December 31, 2021, and as a result the company has put a marketing hold on this product due to poor commercial viability. Adjusted EBITDA for the year ended December 31, 2022 was $3.3 million compared to $2.1 million for the year ended December 31, 2021. Increased adjusted EBITDA for the year ended December 31, 2022 resulted from increased revenues from the sale of AGGRASTAT, ZYPITAMAG and increased sales through Marley Drug. In addition, the prospective change to the amortization of the ZYPITAMAG intangible asset during the fourth quarter of 2021, resulted in lower cost of goods sold during the current year. Offsetting the increase in the current year, was an increase in research and development expenses. Net income for the year ended December 31, 2022 was $1.4 million or $0.13 per share compared to a net loss of $727,000 or $0.07 per share for the year ended December 31, 2021. The main factors contributing to the increase in net income recorded for the year ended December 31, 2022 were the increased revenues from AGGRASTAT, ZYPITAMAG and Marley Drug, a decrease in cost of goods sold as a result of improved inventory management, partially offset by increased research and development expenses primarily due to timing of research and development projects the Company is undertaking. At December 31, 2022, the Company had unrestricted cash totaling $4.9 million, up from $3.7 million of unrestricted cash held as of December 31, 2021. Cash flows from operating activities for the year ended December 31, 2022 totaled $1.8 million compared to $4.0 million for the year ended December 31, 2021. All amounts referenced herein are in Canadian dollars unless otherwise noted. The Company plans to hold an investor conference call in May 2022 to present the results for the three months ended March 31, 2023 with date and dial in information to be provided. The full financial statements are available at and on the Company's website at . Notes The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted for non‑cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three months and year ended December 31, 2022 and 2021 results prepared using IFRS, do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies. About Medicure Inc. Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit . To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com.For more information on Medicure please visit . For additional information about AGGRASTAT®, please visit or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit or refer to the full Prescribing Information. To receive investor and business updates from Medicure, please fill out this form click here to be added to Medicure's e-mail list. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F. AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks. For more information, please contact: Dr. Albert D. Friesen Chief Executive Officer Tel. 888-435-2220 Fax 204-488-9823 E-mail: info@medicure.com Consolidated Statements of Financial Position (expressed in thousands of Canadian dollars, except per share amounts) As at December 31 2022 2021 Assets Current assets: Cash and cash equivalents $ 4,857 $ 3,694 Restricted cash - 3 Accounts receivable 5,635 4,659 Inventories 3,221 3,329 Prepaid expenses 1,134 869 Total current assets 14,847 12,554 Non-current assets: Property and equipment 1,187 1,611 Intangible assets 10,624 11,212 Goodwill 3,177 2,974 Other assets 63 57 Total non-current assets 15,051 15,854 Total assets $ 29,898 $ 28,408 Liabilities and Equity Current liabilities: Accounts payable and accrued liabilities $ 7,128 $ 6,668 Current portion of royalty obligation 179 423 Current portion of acquisition payable 677 634 Current portion of contingent consideration - 293 Current income taxes payable 60 114 Current portion of lease obligations 346 380 Total current liabilities 8,390 8,512 Non-current liabilities Royalty obligation - 65 Acquisition payable - 591 Contingent consideration - 40 Lease obligations 503 789 Total non-current liabilities 503 1,485 Total liabilities 8,893 9,997 Equity: Share capital 80,917 80,917 Contributed surplus 10,476 10,429 Accumulated other comprehensive loss (5,458 ) (6,640 ) Deficit (64,930 ) (66,295 ) Total equity 21,005 18,411 Total liabilities and equity $ 29,898 $ 28,408 Consolidated Statements of Net (Loss) Income and Comprehensive (Loss) Income (expressed in thousands of Canadian dollars, except per share amounts) For the year ended December 31 2022 2021 2020 Revenue, net Product sales, net $ 23,065 $ 21,744 $ 11,610 Cost of goods sold 6,990 9,032 6,480 Gross profit 16,075 12,712 5,130 Expenses Selling 7,935 10,312 5,359 General and administrative 4,193 2,697 4,579 Research and development 2,754 1,796 3,299 14,882 14,805 13,237 Other Income: Other Income (346 ) (1,828 ) - (346 ) (1,828 ) - Finance (income) costs: Finance (income) expense, net 206 525 (765 ) Foreign exchange (gain) loss, net (52 ) (31 ) (497 ) 154 494 (1,262 ) Net income (loss) before income taxes $ 1,385 $ (759 ) $ (6,845 ) Income tax recovery (expense) Current (20 ) 32 - Deferred - - - (20 ) 32 - Net profit (loss) $ 1,365 $ (727 ) $ (6,845 ) Item that may be reclassified to profit or loss Exchange differences on translation of foreign subsidiaries: 1,182 (143 ) (746 ) Comprehensive Income (loss) $ 2,547 $ (870 ) $ (7,591 ) Earnings (loss) per share Basic $ 0.13 $ (0.07 ) $ (0.64 ) Diluted $ 0.13 $ (0.07 ) $ (0.64 ) Consolidated Statements of Cash Flows (expressed in thousands of Canadian dollars, except per share amounts) For the year ended December 31 2022 2021 2020 Cash (used in) provided by: Operating activities: Net profit (loss) for the year $ 1,365 $ (727) $ (6,845) Adjustments for: Current income tax expense (recovery) 20 (32) - Amortization of property and equipment 461 406 307 Amortization of intangible assets 1,594 2,739 2,466 Share‑based compensation 47 135 317 Write-down of inventories 38 1,339 682 Change in fair value of contingent consideration (346) (1,803) - Finance (income) expense, net 190 525 (765) Unrealized foreign exchange (gain) loss (52) (31) (497) Change in the following: Accounts receivable (864) 593 5,081 Inventories 166 471 723 Prepaid expenses (194) 305 703 Other assets (2) 99 - Accounts payable and accrued liabilities 568 20 (3,802) Interest received (paid), net (16) 49 22 Income taxes paid (91) - (306) Royalties paid (1,056) (99) (326) Cash flows from (used in) operating activities 1,828 3,989 (2,240) Investing activities: Acquisition of Marley Drug, Inc, net of cash acquired - - (7,238) Repayment of holdback payable - (1,876) - Acquisition of property and equipment (14) (377) (2) Acquisition of intangible assets (296) (441) - Cash flows (used in) from investing activities (310) (2,694) (7,240) Financing activities: Repurchase of common shares under normal course issuer bid - - (522) Repayment of lease liability (355) (316) (244) Cash flows used in financing activities (355) (316) (766) Foreign exchange loss on cash held in foreign currency - (1) (3) Increase (decrease) in cash 1,163 978 (10,249) Cash and cash equivalents, beginning of period 3,694 2,716 12,965 Cash and cash equivalents, end of year $ 4,857 $ 3,694 $ 2,716 SOURCE: Medicure, Inc. View source version on accesswire.com:

Financial StatementAcquisition

100 Deals associated with Sodium Nitroprusside

External Link

KEGG	Wiki	ATC	Drug Bank
D00614	Sodium Nitroprusside	C02DD01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	US	Hoffmann-La Roche, Inc.	10 May 1974
Hypertension	US	Hoffmann-La Roche, Inc.	10 May 1974

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05027360 (Pubmed)	Not Applicable	Acute decompensated heart failure	200	Sodium nitroprusside	ghguralvkq(xtwuyazmyo) = xniykscmpc dhtmvrqgtb (jbdihtedjp, IQR:10 - 27) View more	Positive	06 Aug 2022
Pubmed \| Clin Spine Surg	Not Applicable	-	60	Milrinone	ntdatenopx(cftahzjkut) = gmagespdos isxegdqave (tlbhboqnow )	-	01 Oct 2019
				Sodium Nitroprusside	ntdatenopx(cftahzjkut) = oubefcvgis isxegdqave (tlbhboqnow )
NCT01048125 (CTgov)	Not Applicable	Cardiomyopathies \| Takotsubo Cardiomyopathy	2	Sympathetic Nerve Activity (Study Group)	ppwcaekewo(xakulqypzo) = pxltlokyro eqietqjptj (nzdojwbzfk, ginecdiqqe - ofckzjclju) View more	-	23 Nov 2016
				Sympathetic Nerve Activity (Control)	ppwcaekewo(xakulqypzo) = mretvgpbgz eqietqjptj (nzdojwbzfk, jprdujicoo - ladwccszya) View more
NCT00945256 (CTgov)	Phase 1	-	62	Aerobic Exercise (Young Aerobic Exercise)	vyvxlwqyrf(fkjvchzkoc) = knzzzrbzit lpbostjnwo (qekxlxuhud, gymzhxhhao - eklcmqmblj) View more	-	05 Jan 2016
				Aerobic Exercise (Elderly Aerobic Exercise)	vyvxlwqyrf(fkjvchzkoc) = kcluukexis lpbostjnwo (qekxlxuhud, iocvmymfua - uidkfqkehe) View more
NCT00166166 (CTgov)	Phase 2	Hyperlipidemias	174	Tetraethylammonium (TEA)+Fluconazole+L-NG-monomethyl Arginine (L-NMMA)+Acetylcholine+Saline+Sodium nitroprusside (Healthy Controls)	dsitnqnwkz(ytyxnpwlbp) = tsjbkqbwxu sbzriywmuz (hbdicmzupy, ogvaqfgzbv - gyrfuxoazw) View more	-	13 May 2015
				Tetraethylammonium (TEA)+Fluconazole+L-NG-monomethyl Arginine (L-NMMA)+Acetylcholine+Saline+Sodium nitroprusside (Risk Factors)	dsitnqnwkz(ytyxnpwlbp) = mhizctaxzd sbzriywmuz (hbdicmzupy, qbavomybua - zpygqobcst) View more
ASN2010	Not Applicable	Renal injury	-	Sodium Nitroprusside	ykterwqvrg(jsiwrbrdha) = gnvuhkmpwm lfygausnpu (umukpzjoth ) View more	Positive	16 Nov 2010
NCT00690534 (Pubmed \| Diabetes)	Phase 1	-	12	Insulin alone	agosgpqnym(qswzqfjxby) = sqcrzpqomq drfqihvuud (xgnolqldgj ) View more	-	01 Nov 2010
				Insulin plus sodium nitroprusside (SNP)	agosgpqnym(qswzqfjxby) = sknevhlaau drfqihvuud (xgnolqldgj ) View more
ARVO2009	Not Applicable	Ocular Hypertension	13	Sodium Nitroprusside (SNP)	ipijpqrhih(reyphndhmr) = tvudbphbkv fnblbmvkub (rgpoiwupaa ) View more	-	01 Apr 2009
				Sodium Nitroprusside	ipijpqrhih(reyphndhmr) = uptzeqvidj fnblbmvkub (rgpoiwupaa ) View more
ARVO2009	Not Applicable	Glaucoma With Elevated Episcleral Venous Pressure	13	Sodium Nitroprusside	jwzsvmifas(ivvtmrwsvv) = fupnzbyupo syjgdexijx (peronkjeie ) View more	-	01 Apr 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis